{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Food+Effect+cohort&page=8", "query": { "intervention": "Food Effect cohort", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 218, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Food+Effect+cohort&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Food+Effect+cohort&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:15:05.519Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06998407", "title": "ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HR+/HER2- Breast Cancer", "HR+, HER2-, Advanced Breast Cancer" ], "interventions": [ { "name": "AVZO-021", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "AVZO-023", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avenzo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2025-08-20", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-11-15T12:15:05.519Z", "location_count": 16, "location_summary": "Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06998407" }, { "nct_id": "NCT05902988", "title": "A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "High Grade Serous Adenocarcinoma of Ovary", "Squamous Non-small-cell Lung Cancer", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Ovarian Carcinosarcoma", "Uterine Carcinosarcoma", "Uterine Serous Carcinoma", "Endometrium Cancer", "Chromosomal Instability" ], "interventions": [ { "name": "VLS-1488", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Volastra Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2023-10-18", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-11-15T12:15:05.519Z", "location_count": 14, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05902988" }, { "nct_id": "NCT04493671", "title": "Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Disease", "Tuberculosis, Pulmonary", "Tuberculosis", "Multi Drug Resistant Tuberculosis", "Drug Sensitive Tuberculosis", "Drug-resistant Tuberculosis", "Mycobacterium Tuberculosis Infection" ], "interventions": [ { "name": "TBAJ-876 suspension", "type": "DRUG" }, { "name": "Placebo suspension", "type": "DRUG" }, { "name": "TBAJ-876 100 mg tablet", "type": "DRUG" }, { "name": "TBAJ-876 25 mg tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Global Alliance for TB Drug Development", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "19 Years to 50 Years" }, "enrollment_count": 137, "start_date": "2020-06-08", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-11-15T12:15:05.519Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493671" }, { "nct_id": "NCT04718181", "title": "Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Muscular Atrophy, Spinal" ], "interventions": [ { "name": "risdiplam", "type": "DRUG" }, { "name": "omeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 131, "start_date": "2021-02-01", "completion_date": "2023-01-28", "has_results": false, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-11-15T12:15:05.519Z", "location_count": 4, "location_summary": "Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Springfield", "state": "Missouri" }, { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04718181" }, { "nct_id": "NCT07563894", "title": "Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-07799933 tablets with PF-07799544 fasted", "type": "DRUG" }, { "name": "PF-07799933 film-coated tablets with PF-07799544 fasted", "type": "DRUG" }, { "name": "PF-07799933 film-coated tablets with PF-07799544 fed", "type": "DRUG" }, { "name": "PF-07799933 film-coated tablets fasted", "type": "DRUG" }, { "name": "PF-07799933 film-coated tablets following rabeprazole pretreatment fasted", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 16, "start_date": "2026-04-10", "completion_date": "2026-06-26", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-11-15T12:15:05.519Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07563894" }, { "nct_id": "NCT00817414", "title": "A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "LCI699-matching placebo", "type": "DRUG" }, { "name": "LCI699", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 63, "start_date": "2009-01-14", "completion_date": "2009-08-12", "has_results": true, "last_update_posted_date": "2021-06-02", "last_synced_at": "2026-11-15T12:15:05.519Z", "location_count": 10, "location_summary": "Beverly Hills, California • Buena Park, California • Harbor City, California + 7 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Buena Park", "state": "California" }, { "city": "Harbor City", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00817414" }, { "nct_id": "NCT04034992", "title": "A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of Life", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Kidney Disease" ], "interventions": [], "intervention_types": [], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1052, "start_date": "2019-09-11", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2024-03-06", "last_synced_at": "2026-11-15T12:15:05.519Z", "location_count": 11, "location_summary": "Riverside, California • San Francisco, California • Sanford, Florida + 8 more", "locations": [ { "city": "Riverside", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sanford", "state": "Florida" }, { "city": "Sebring", "state": "Florida" }, { "city": "Plymouth", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04034992" }, { "nct_id": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Small Cell Lung Cancer", "Ovarian Cancer", "Gastric Cancer", "Hormone-receptor-positive Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer", "Advanced Solid Tumor", "Endometrial Cancer", "Prostate Cancer", "TNBC - Triple-Negative Breast Cancer", "GastroEsophageal Cancer", "Bladder Cancer" ], "interventions": [ { "name": "BG-68501", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "BGB-43395", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2024-03-11", "completion_date": "2027-08-27", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-15T12:15:05.519Z", "location_count": 6, "location_summary": "Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06257264" }, { "nct_id": "NCT03491930", "title": "Weight Loss Using a Feedback Device in Obese People With the Metabolic Syndrome", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Weight Loss", "Obesity", "Pre-Diabetes", "Metabolic Syndrome" ], "interventions": [ { "name": "VA MOVE! Coach app", "type": "DEVICE" }, { "name": "Telephone Coaching", "type": "BEHAVIORAL" }, { "name": "Standard of Care for weight loss.", "type": "BEHAVIORAL" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2018-06", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2018-10-24", "last_synced_at": "2026-11-15T12:15:05.519Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03491930" }, { "nct_id": "NCT04906434", "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Liver Cancer" ], "interventions": [ { "name": "ABSK-011", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbisko Therapeutics Co, Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 200, "start_date": "2020-02-26", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-11-15T12:15:05.519Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906434" } ] }